[go: up one dir, main page]

WO2008148490A8 - Hsp27 as biomarker for alzheimer's disease - Google Patents

Hsp27 as biomarker for alzheimer's disease Download PDF

Info

Publication number
WO2008148490A8
WO2008148490A8 PCT/EP2008/004235 EP2008004235W WO2008148490A8 WO 2008148490 A8 WO2008148490 A8 WO 2008148490A8 EP 2008004235 W EP2008004235 W EP 2008004235W WO 2008148490 A8 WO2008148490 A8 WO 2008148490A8
Authority
WO
WIPO (PCT)
Prior art keywords
hsp27
disease
alzheimer
level
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/004235
Other languages
French (fr)
Other versions
WO2008148490A1 (en
Inventor
Peter Berndt
Bernd Bohrmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of WO2008148490A1 publication Critical patent/WO2008148490A1/en
Publication of WO2008148490A8 publication Critical patent/WO2008148490A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention relates to a method for assessing Alzheimer's disease in vitro comprising measuring the level of HSP27, or a variant thereof in a sample collected from an individual, wherein an altered level of said protein, or a variant thereof, is indicative that said individual suffers from Alzheimer's disease. Furthermore, the present invention relates to a method for monitoring the progression of the Alzheimer's disease in vitro comprising measuring the level of HSP27, or a variant thereof in a sample collected from an individual, wherein an altered level of HSP27 compared with an earlier measurement of the level of HSP27, or a variant thereof, is indicative for the progression of Alzheimer's disease of said individual.
PCT/EP2008/004235 2007-06-04 2008-05-28 Hsp27 as biomarker for alzheimer's disease Ceased WO2008148490A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07109516 2007-06-04
EP07109516.0 2007-06-04

Publications (2)

Publication Number Publication Date
WO2008148490A1 WO2008148490A1 (en) 2008-12-11
WO2008148490A8 true WO2008148490A8 (en) 2009-11-19

Family

ID=39681049

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/004235 Ceased WO2008148490A1 (en) 2007-06-04 2008-05-28 Hsp27 as biomarker for alzheimer's disease

Country Status (1)

Country Link
WO (1) WO2008148490A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3142708A4 (en) * 2014-05-16 2018-01-17 Vitruvian Biomedical, Inc. Diagnostic test and treatment/prevention of alzheimer's disease

Also Published As

Publication number Publication date
WO2008148490A1 (en) 2008-12-11

Similar Documents

Publication Publication Date Title
EP3355059A3 (en) Biomarker assay of neurological condition
HK1206423A1 (en) Oligomeric a in the diagnosis, prognosis, and monitoring of alzheimer's disease
WO2010053587A3 (en) Methods of monitoring conditions by sequence analysis
CY1110116T1 (en) Neuroendocrine indicators for depression
WO2008148072A3 (en) Disease-associated genetic variations and methods for obtaining and using same
IN2014MN02060A (en)
ATE554389T1 (en) APEX AS A MARKER FOR LUNG CANCER
WO2011064225A8 (en) Novel diagnostic method for the diagnosis of alzheimer's disease or mild cognitive impairment
EP2387711A4 (en) METHODS FOR DETERMINING PATIENT RESPONSE BY MEASURING HER-3
EP1869401A4 (en) METHOD FOR PERFORMING HIGH RESOLUTION MEASUREMENTS OF ASPHERIC SURFACES
AU2010202926B2 (en) Markers and methods relating to the assessment of Alzheimer's disease
PL2021794T3 (en) Use of protein s100a 12 as a marker for colorectal cancer
WO2010061283A3 (en) Biomarkers for diagnosing and detecting the progression of neurodegenerative disorders, in particular of amyotrophic lateral sclerosis
WO2010136163A8 (en) Secernin-1 as a marker for cancer
EP2889591A3 (en) Method of Determining Vehicle Scale Health and Suitability for Use via Weight Transfer Pattern Analysis
WO2012078623A3 (en) Biomarkers for monitoring treatment of neuropsychiatric diseases
EP2557421A3 (en) Altered mitochondrial activity in diseases resulting from oxidative stress
WO2006113245A3 (en) Methods for measuring glycan levels of proteins
HK1209832A1 (en) Method and kit for determination of free copper in serum
WO2008131261A3 (en) Peptide biomarkers of cardiovascular disease
WO2011109112A3 (en) Method of detecting tau protein and tau fragments in serum
DE602007006671D1 (en) USE OF NNMT AS A MARKER FOR LUNG CANCER
WO2013064702A3 (en) Probes for diagnosis and monitoring of neurodegenerative disease
WO2014177867A3 (en) Differentially expressed biomarkers for alzheimer's disease
WO2010000467A8 (en) Asc as a marker for lung cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08758819

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08758819

Country of ref document: EP

Kind code of ref document: A1